Compare Greenwood Sejahtera Tbk. (GWSA) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Greenwood Sejahtera Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Greenwood Sejahtera Tbk. trades at Rp167 (market cap 1.34T, 929.4K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Greenwood Sejahtera Tbk. is far larger — about 12.8× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| GWSA | SCPI | |
|---|---|---|
Market Cap | 1.34T | 104.4B |
Volume | 929.4K | — |
Lot | 9.29K | — |
Turnover | 156.04M | — |
Average Price | 167.89 | — |
Value | 156.04M | — |
Indicative Equilibrium Price | 167 | — |
Indicative Equilibrium Volume | 15 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Greenwood Sejahtera Tbk.
Greenwood Sejahtera is part of KG Global Development. On the begining, the company have a relation with Jababeka group, which own the land that has been used to builit TCC Batavia.PT Greenwood Sejahtera, company that developing The City Center Batavia (TCC Batavia), on December 23, 2011. The City Center Batavia is a superblock, mix used development project on top of 2,1 hectares of land. Its first tower is a skycrapper building: a tower with 46 storey, plus an 8 storey annex. According to the masterplan, Greenwood Sejahtera will build 3 tower on the site. The other tower will be completed in 2017 and the area will be expanded to 5.4 hectares. Its ground breaking ceremony is on September 12, 2009.
Read more on GWSA →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
